PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 730-738

  Zhang, Hongbing ^a,b,c,e   Bajraszewski, Natalia ^b   Wu, Erxi ^d   Wang, Hongwei ^b   Moseman, Annie P ^d   Dabora, Sandra L ^b   Griffin, James D ^c   Kwiatkowski, David J ^b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; SOMATOMEDIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; FIBROBLAST; GENE DELETION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; MICE; MICE, MUTANT STRAINS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 33847394119     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28984     Document Type: Article

References (49)

1. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell. 103:211-225.
2. Cully, M., You, H., Levine, A.J., and Mak, T.W. 2006. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer. 6:184-192.
3. Thomas, G.V. 2006. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 16:78-84.
4. Hay, N. 2005. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8:179-183.
5. Samuels, Y., and Ericson, K. 2006. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18:77-82.
6. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4:988-1004.
7. Schlessinger, J. 2002. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 110:669-672.
8. Johnson, B.E., and Janne, P.A. 2005. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65:7525-7529.
9. Jones, A.V., and Cross, N.C. 2004. Oncogenic derivatives of platelet-derived growth factor receptors. Cell. Mol. Life Sci. 61:2912-2923.
10. Samuels, Y., et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:554.
11. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:11-22.
12. Parsons, D.W., et al. 2005. Colorectal cancer: mutations in a signalling pathway. Nature. 436:792.
13. Parsons, R. 2004. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15:171-176.
14. Kwiatkowski, D.J., et al. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525-534.
15. Zhang, H., et al. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through down-regulation of PDGFR. J. Clin. Invest. 112:1223-1233. doi:10.1172/JCI200317222.
16. Potter, C.J., Pedraza, L.G., and Xu, T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:658-665.
17. Corradetti, M.N., Inoki, K., Bardeesy, N., DePinho, R.A., and Guan, K.L. 2004. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18:1533-1538.
18. Kwiatkowski, D.J., and Manning, B.D. 2005. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14:R251-R258.
19. Li, Y., Corradetti, M.N., Inoki, K., and Guan, K.L. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29:32-38.
20. Cai, S.L., et al. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 173:279-289.
21. Jaeschke, A., et al. 2002. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:217-224.
22. Harrington, L.S., et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
23. Shah, O.J., Wang, Z., and Hunter, T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656.
24. Ross, R., Raines, E.W., and Bowen-Pope, D.F. 1986. The biology of platelet-derived growth factor. Cell. 46:155-169.
25. Tallquist, M., and Kazlauskas, A. 2004. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 15:205-213.
26. Andrews, A., et al. 1999. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 40:2683-2689.
27. Chen, N., et al. 2001. Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoylphorbol-13-acetate-induced signal transduction. J. Biol. Chem. 276:46722-46728.
28. Maxwell, M., et al. 1990. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. 86:131-140.
29. Gilbertson, R.J., and Clifford, S.C. 2003. PDGFRB is overexpressed in metastatic medulloblastoma. Nat. Genet. 35:197-198.
30. Dolloff, N.G., et al. 2005. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 24:6848-6854.
31. Izumi, H., et al. 2001. Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J. Cell Sci. 114:1533-1544.
32. Hackzell, A., Uramoto, H., Izumi, H., Kohno, K., and Funa, K. 2002. p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J. Biol. Chem. 277:39769-39776.
33. Molander, C., Hackzell, A., Ohta, M., Izumi, H., and Funa, K. 2001. Sp1 is a key regulator of the PDGF beta-receptor transcription. Mol. Biol. Rep. 28:223-233.
34. Hara, K., et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110:177-189.
35. Sarbassov, D.D., et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-1302.
36. Sarbassov, D.D., et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22:159-168.
37. Saito, Y., Haendeler, J., Hojo, Y., Yamamoto, K., and Berk, B.C. 2001. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 21:6387-6394.
38. Kratchmarova, I., Blagoev, B., Haack-Sorensen, M., Kassem, M., and Mann, M. 2005. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science. 308:1472-1477.
39. Manning, B.D., et al. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19:1773-1778.
40. Astrinidis, A., and Henske, E.P. 2005. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 24:7475-7481.
41. Govindarajan, B., et al. 2003. Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin. Cancer Res. 9:3469-3475.
42. Han, S., et al. 2004. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res. 64:812-816.
43. O'Reilly, K.E., et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
44. Franz, D.N., et al. 2006. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59:490-498.
45. Kenerson, H., Dundon, T.A., and Yeung, R.S. 2005. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr. Res. 57:67-75.
46. Lee, L., et al. 2005. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 42:213-227.
47. El-Hashemite, N., Zhang, H., Walker, V., Hoffmeister, K.M., and Kwiatkowski, D.J. 2004. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 64:3436-3443.
48. Finlay, G.A., et al. 2004. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J. Biol. Chem. 279:23114-23122.
49. You, M.J., et al. 2002. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 99:1455-1460.